Benzinga | Jan 22, 2021 07:02AM EST

Spectrum Pharma Highlights 2 Oral Presentations At Upcoming International Association for the Study of Lung Cancer Conference Jan. 28-31

Spectrum Pharmaceuticals (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced an oral presentation on updated efficacy, safety, and dosing management of poziotinib from Cohorts 1 and 2 of the ZENITH20 clinical trial. In addition, Spectrum also announced an oral presentation on the structural classification of atypical EGFR mutations and their patterns of drug sensitivity. These presentations will take place as part of the IASLC 2020 World Conference on Lung Cancer (#WCLC20) hosted by the International Association for the Study of Lung Cancer (IASLC) taking place virtually January 28-31, 2021. Details of the presentations are as follows:

Title: Updated efficacy, safety, and dosing management of poziotinib in previously treated EGFR and HER2 exon 20 NSCLC patients

Speaker: Robin Cornelissen, Ph.D., M.D.

Session: Expanding Targetable Genetic Alterations in NSCLC Mini Oral Session

Date and Time: January 31, 2021, 14:20 SGT (January 30, 2021 10:20 p.m. PT)

Presentation Number: MA11.04

Title: Structural classification of atypical EGFR mutations identifies four major subgroups with distinct patterns of drug sensitivity

Speaker: Jacqulyne P. Robichaux. Ph.D.

Session: Tumor Biology: Focus on EGFR Mutation, DNA Repair and Tumor Microenvironment Mini Oral Session

Date and Time: January 31, 2021, 17:20 SGT (January 31, 2021 1:20 a.m. PT)

Presentation Number: MA13.07

Access to the presentations is available to members of IASLC and can be found here: https://wclc2020.iaslc.org/registration/.